The human GH family consists of five genes, including the placental chorionic somatomammotropins (CS), within a single locus on chromosome 17. Based on nuclease sensitivity, the entire GH/CS locus is accessible in pituitary chromatin, yet only GH-N is expressed. Previously, we reported a P sequence element ( 
The human GH family consists of five genes, including the placental chorionic somatomammotropins (CS), within a single locus on chromosome 17. Based on nuclease sensitivity, the entire GH/CS locus is accessible in pituitary chromatin, yet only GH-N is expressed. Previously, we reported a P sequence element (263P) capable of repressing placental CS promoter activity in transfected pituitary (GC) cells. T HE HUMAN GH (hGH) gene family consists of five highly related genes contained within a single 47-kb locus on chromosome 17 (1) . Despite a remarkable degree of similarity in gene structure and flanking DNA sequences, this family displays strictly regulated patterns of tissue-specific expression (1) . GH-N is the only member of the family that is highly expressed in the pituitary (1) , even though the entire locus is sensitive to endonuclease and thus appears to have an open chromatin structure (2) . The remaining members of the family, GH variant (GH-V) and the chorionic somatomammotropins (CS-A, CS-B, and CS-L), are specifically expressed in placental syncytiotrophoblast (1) . Conserved elements termed "P" sequences have been identified approximately 2 kb upstream of the transcription initiation site of each of the placental GH/CS genes, but not pituitary GH-N (1). The location of these repeats made them ideal candidates for involvement in local regulation of the GH locus. Further analysis of the P sequences identified a 263-bp core element (263P) based on its capacity to repress the in vitro pituitary activity of the CS-A promoter that is seen after gene transfer (3) . To date, the ability of 263P to repress the activity of the CS-A promoter has not been tested in vivo; however, intriguing data regarding a potential role for 263P in placental activation of the locus have emerged. Analysis of histone acetylation levels within the GH locus of human term placenta chromatin has revealed a peak of histone hyperacetylation associated with 263P (4) . The ability of 263P to repress CS-A promoter activity in pituitary cells in vitro, as well as its potential to enhance placental expression in vivo (implied by hyperacetylation), opens the possibility that this sequence may be an integral component in regulating tissue-specific expression of the human GH locus.
Regions of protein binding within 263P include P sequence elements A and B (PSE-A and PSE-B), and we reported nuclear factor-1 (NF-1) recognition of PSE-B. We now provide evidence for multiple interactions on PSE-A, including binding of the regulatory factor X (RFX)
We have focused our attention on identifying the factors involved in 263P regulatory complexes. At the time 263P was originally identified, two regions of protein-DNA interactions were visualized by endonuclease protection assay, P sequence element-A (PSE-A) and PSE-B. It was not resolved whether these regions represented one or more protein-DNA interactions (3). Recently, we have shown that members of the nuclear factor-1 (NF-1) family of transcription factors, known to mediate both transcriptional activation and repression (5) , can recognize PSE-B (6). The binding of NF-1 family members to PSE-A was not detected despite, paradoxically, the ability of a consensus NF-1 element to compete for the PSE-A footprint pattern in nuclease protection assays (6) . We now provide evidence for multiple interactions at PSE-A, which offers an explanation for this paradox. More importantly, the ability of the NF-1 family and regulatory factor X1 (RFX1) to participate in the 263P complex in vitro, as well as in situ, and the capacity for interactions between RFX1 and NF-1 family members are described. These observations define the human GH locus as a novel regulatory target for the RFX family and allow us to propose a model for involvement of the 263P complex in repression of the placental GH/CS genes in the pituitary.
RESULTS

Specific Complex Formation on PSE-A Is Seen by EMSA
When 263P was incubated with pituitary GC cell nuclear extract in a nuclease protection assay, two characteristic footprint regions, PSE-A and PSE-B, were observed (Fig. 1A) . As previously reported, both PSE-A and PSE-B oligonucleotides compete for both protected regions (3, 6) . Analysis of PSE-A by EMSA revealed several DNA-protein complexes with pituitary cell nuclear protein (Fig. 1B) . Complexes I-IV were readily competed by a 5-fold excess of unlabeled PSE-A competitor, but not by a 50-fold excess of unlabeled PSE-B competitor, suggesting specific, high-affinity protein binding events.
Determination of the Core Sequences Within PSE-A for Specific Pituitary Complex Formation
Examination of PSE-A sequences for known protein binding DNA elements (7) reveals several candidates, including a putative RFX site and a half-site for NF-1 binding ( Fig. 2A) . To determine essential or core sequences involved in the formation of both PSE-A and 263P specific complexes, a series of scanning mutations were created within PSE-A ( Fig. 2A) . These mutations did not create additional known recognition sequences based on database analysis. Using EMSA and pituitary GC cell protein, the mutated oligonucleotides were then tested for their ability to compete complexes I-IV from the PSE-A probe (Fig. 2B ). Whereas none of the PSE-A mutations were able to efficiently compete complexes III and IV, Am1, Am4, Am5, and Am6 were competitors of complex I with incomplete competition of complex II. The Am2 and Am3 mutations, however, were unable to effectively compete for either complex I or II and thus defined a core region within PSE-A for their formation. This core region localizes to a putative X-box motif [5Ј-GTNRCC(0-3N)RGYAAC-3Ј] (8) recognized by the RFX family of transcription factors ( Fig. 2A) .
To determine those PSE-A sequences that were important for competition of 263P footprint patterns, the PSE-A scanning mutations, along with a 3Ј truncated form of PSE-A (PSE-Adel), were used as competitors in a nuclease protection assay (Fig. 2C) . Mutations PSE-Am2 and PSE-Am3, which encompass the putative RFX binding site, as well as wild-type PSE-A, PSE-Am1, PSE-Am4, and PSE-Am5, were able to compete the 263P footprint pattern (Fig. 2C) . In contrast, the 3Ј-mutation (PSE-Am6) and truncation (PSE-Adel) of PSE-A, which disrupt the NF-1 half-site ( Fig. 2A) , were able to compete the nuclease protection pattern at 1000-fold pmol excess of the 263P probe, although not as efficiently as wild-type PSE-A (Fig. 2C) . At 5000-fold pmol excess, all of the PSE-A mutations competed the nuclease protection pattern (data not shown).
RFX1 Is Capable of Binding to PSE-A in Pituitary Extracts in Vitro
To assess the ability of the RFX family to directly bind to PSE-A, the EF-C/MDBP RFX1 element and RFX1 antibodies (9) were used as specific competitors in EMSA (Fig. 3) . The EF-C/MDBP element was previously shown to bind a chemically synthesized RFX1 DNA binding domain (10) and was used as a representative RFX1 binding site in the absence of a defined RFX consensus sequence. The wild type, but not a mutation of the EF-C/MDBP site, was able to efficiently compete for both complexes I and II when PSE-A was used as a probe with pituitary GC cell nuclear protein (Fig. 3A, closed arrowheads) . These same complexes were also competed by RFX1 antibodies, with evidence of supershifted aggregates in the well, as previously observed with this antibody (11) . Neither competition of complexes I and II nor supershifts were observed when RFX2 and RFX3 antibodies were used with pituitary GC nuclear extract and the PSE-A probe in EMSA (Fig. 3B) .
NF-1 Can Interact with PSE-A in Pituitary Extracts in the Absence of RFX1 Binding
Our previous investigation was unable to detect direct binding of the NF-1 family to PSE-A (6). To assess the possibility that NF-1 can interact with PSE-A in the absence of RFX1 binding, PSE-Am2 was used as a probe for EMSA. The mutation contained in PSE-Am2 is located within the putative RFX site ( Fig. 2A) and was unable to compete for complexes I or II from a PSE-A probe (Fig. 2B) . When the PSE-Am2 oligonucleotide was used as a probe for EMSA with pituitary GC nuclear extract, complexes I and II were not detected (Fig. 4A) ; however, an additional complex was observed compared with the pattern seen with the wild-type PSE-A probe (compare Fig. 4A with Fig. 3) . A consensus, but not a mutant, NF-1 DNA element was able to efficiently compete for this additional complex (Fig. 4A, open arrowhead) . This same complex was also competed by NF-1 antibodies with evidence of a supershifted band (Fig. 4B, closed arrowhead) . In contrast to the PSE-Am2 probe, no evidence of NF-1 binding was detected when PSE- Am6 was used as an EMSA probe (Fig. 4B) . The PSE-Am6 mutation disrupts the NF-1 1/2 site ( Fig.  2A) , and the pattern of complexes on this probe resembles that of the wild-type PSE-A (compare Fig.  4B with Fig. 3 ).
Both the PSE-B/NF-1 Binding Site and the RFX Site within PSE-A Contribute to the Pituitary Repressor Function of 263P
To determine whether the RFX site within PSE-A contributes to 263P repressor activity, mutations within 263P were created and tested in transfected rat pituitary GC cells. The PSE-Am2 mutation, shown to be unable to form complexes I or II and thus bind RFX1 (Fig. 4A) , was introduced into 263P by site-directed mutagenesis. The resulting fragment was placed upstream of the CS-A promoter to create Am2.CSp.Luc. A PSE-B mutation, shown previously to be unrecognized by members of the NF-1 family (6), was likewise introduced into 263P upstream of the CS-A promoter to generate Bm.CSp.Luc. A significant loss of repressor function was seen with Am2.CSp.Luc (P Ͻ 0.001, n ϭ 9) and Bm.CSp.Luc (P Ͻ 0.001, n ϭ 9) compared with wild-type 263P (263PCSp.Luc) (Fig. 5) .
The relative luciferase activity of Am2.CSp.Luc and Bm.CSp.Luc was also compared with the luciferase activity of CSp.Luc (arbitrarily set to 100%) to assess whether either of the single mutations had completely abolished 263P repressor function. This was not the case, as both single mutants displayed a significant decrease in activity compared with the CSp.Luc control (Fig. 5) . Specifically, Am2.CSp.Luc and Bm.CSp.Luc repressed CS-A promoter activity by 21% (P Ͻ 0.01, n ϭ 9) and 25% (P Ͻ 0.001, n ϭ 9), respectively. In contrast, introduction of mutations at both the RFX1/PSE-A and NF-1/PSE-B sites within 263P (Am2/Bm.CSp.Luc) abolished 263P repressor activity, as Am2/Bm.CSp.Luc and CSp.Luc showed no significant difference in activity (n ϭ 9).
RFX1 Has the Capacity to Interact with Members of the NF-1 Family
The proximity of the PSE-A/RFX and PSE-B/NF-1 sites in 263P, as well as the ability of each element to compete for the characteristic footprint pattern on 263P, raises the possibility of an interaction between RFX1 and one or more members of the NF-1 family (NF-1A, NF-1B, NF-1C, and NF-1X). This was investigated by immunoprecipitation and protein blotting. In the absence of specific antibodies to each of the different NF-1 family members, c-myc epitope-tagged NF-1s as well as RFX1 were coexpressed in JAR cells.
Overexpression of each of the NF-1 family members was detected in the lysates by protein blotting and immunodetection with a c-myc antibody (Fig. 6A ). RFX1 overexpression above endogenous levels was also detected in lysates from transfected JAR cells (Fig. 6B) . The ability of RFX1 antibodies to immunoprecipitate RFX1 was confirmed (Fig. 6C) . The myc epitope tag of each NF-1 species was assessed by Hybrid luciferase (Luc) genes were used to assess the effect of introducing nonbinding RFX1 and NF-1 mutations within 263P on Ϫ492/ϩ6 CS-A promoter (CS-Ap) activity in GC cells. DNA uptake was controlled through cotransfection with pRL-TKp. Results, corrected, are expressed as a percentage of the activity of CSp.Luc, which was arbitrarily set to 100%. The basal firefly Luc/Renilla Luc and firefly Luc values for CSp.Luc were 2.56 Ϯ 0.10 and 70,000 Ϯ 3,600 (n ϭ 9), respectively. Bars represent SEM. immunoblotting following immunoprecipitation with polyclonal RFX1 or, as an unrelated control, dorsolateral protein (DLP)-specific antibodies. In the case of immunoprecipitation with RFX1 antibodies, bands corresponding to tagged NF-1A, NF-1B, NF-1C, and NF-1X were detected with antibodies to c-myc (Fig.  6D) . In contrast, none of the bands corresponding to tagged NF-1s were seen as a result of immunoprecipitation with DLP antibodies (Fig. 6E) .
NF-1 and RFX1 Associate with 263P Sequences in Human Pituitary Chromatin
Chromatin immunoprecipitation (ChIP) assays were used to investigate the ability of NF-1 and RFX1 to associate with 263P in human pituitary tissue samples. The ability of the NF-1 antibody to immunoprecipitate all four NF-1 family members as well as a commercial RFX1 antibody to immunoprecipitate RFX1 was confirmed (Fig. 7 ). These same conditions were then used to immunoprecipitate cross-linked chromatin from human pituitary nuclei. Following cross-link reversal and DNA isolation, 263P and fibroblast growth factor (FGF)-16 exon 3 sequences were amplified from both input and immunoprecipitated (bound) DNA samples by PCR. FGF-16 is a member of the FGF family expressed specifically in embryonic brown adipose and adult cardiac tissue (12); PCR with the FGF-16 exon 3 primers was thus used as a measure of nonspecific sequences present in our bound sample. PCR products were electrophoresed and densitometry used to assess levels from digital images. To correct for differences between primer pair efficiency, bound values are expressed as a ratio of the input value. When the NF-1 antibody was used for ChIP, the mean bound/ input (B/I) ratio for 263P was 0.4, which was significantly higher than the mean FGF-16 exon 3 B/I ratio of 0.18 (P Ͻ 0.01, n ϭ 4) (Fig. 8) . A 263P B/I ratio of 0.63 was also significantly higher than the FGF-16 exon 3 B/I ratio of 0.31 (P Ͻ 0.05, n ϭ 4) when the RFX1 antibody was used for ChIP (Fig. 8) .
The Detection of the NF-1/RFX1 263P Complexes in Pituitary Tissue Correlates with a Lack of Both 263P and CS Promoter Hyperacetylation
ChIP assays with an antibody to the hyperacetylated form of histone H4 were used to assess the hyperacetylation status of various regions of the GH/CS locus in human pituitary tissue as well as human term placenta. When cross-linked chromatin from pituitary tissue was immunoprecipitated with the hyperacetylated H4 antibody, a significant increase in the mean B/I of the GH promoter (1.31) over the mean (control) FGF-16 exon 3 B/I (0.35) was detected (P Ͻ 0.001, n ϭ 3), whereas no significant difference was seen for the mean B/I of either the CS promoter (0.32) or 263P (0.62) above the FGF-16 background in these same assays (Fig. 9) .
In term placenta chromatin, evidence of histone H4 hyperacetylation at both the CS and GH promoters, as well as 263P, was evident (Fig. 9) . ChIP with hyperacetylated H4 antibody yielded a mean B/I of 1.77 for the GH promoter, 2.57 for the CS promoters, and 1.8 for 263P, all of which were significantly higher than the FGF-16 exon 3 B/I of 1.03 (P Ͻ 0.05, P Ͻ 0.05, and P Ͻ 0.01, respectively; n ϭ 3).
DISCUSSION
P sequences, and specifically the 263P region, have been implicated in the expression and regulation of the human GH family in vitro and in vivo (3, 4, 6 ). The 263P region contains two sites of direct protein-DNA interactions that are visualized by nuclease protection, namely PSE-A and PSE-B. We have shown previously that PSE-B is a binding site in vitro for NF-1, a family of transcription factors known to be involved in both activation and repression of genes (5) . In the present study we used a combination of structural and functional assays to assess PSE-A, with a view to further characterize the 263P complex. Our data define the human GH locus as a novel regulatory target for the RFX winged-helix family and provide evidence for multiple interactions at PSE-A. In addition, we have described, for the first time, the potential for NF-1 and RFX1 to participate in a common regulatory complex and have identified association of these factors with 263P in pituitary chromatin. We also observed an inverse relationship between association of NF-1 and RFX1 and the presence of 263P and CS promoter hyperacetylation. Taken together, our data support the idea that the presence of the NF-1/RFX1 263P complex in vivo negates the formation of a potential enhancer complex and/or hyperacetylated chromatin structure, leading to the lack of placental gene expression in pituitary tissue.
Analysis of PSE-A in vitro has revealed a core sequence for pituitary protein-DNA interactions that localizes to a region containing an X-box motif (5Ј-GTNRCC(0-3N)RGYAAC-3Ј) recognized by the regulatory factor X (RFX) family of transcription factors (Fig. 2, A and B) (8) . Through EMSA, we have confirmed that PSE-A is an RFX1 DNA element (Fig. 3) and that this element can compete the 263P footprint pattern (Fig. 1A) . In addition, our functional data indicate a role for RFX in the repressor action of 263P in pituitary cells after gene transfer (Fig. 5) , an activity that helps define this element (3). The human GH family, and specifically PSE-A, represents a novel regulatory target for the RFX family. In mammals, the RFX family consists of five members (13) . RFX1, RFX2, and RFX3 are expressed ubiquitously (14, 15) , whereas RFX4 is expressed specifically in testis (16) , and RFX5 has been identified as being essential for expression of the tissue-specific MHC class II genes (17) . Candidate target genes for RFX1 include ribosomal protein L30, interleukin-5 receptor ␣, and proliferating cell nuclear antigen (11, 18, 19) ; targets have not been identified for RFX-2 or RFX-3. RFX1, but not RFX2 and RFX3, binding to PSE-A was detected (Fig. 3) ; however, a negative result does not rule out participation of either RFX2 or RFX3 in a 263P complex. These family members may be absent, present at low levels, or modified and unable to bind. Nonetheless, the competition of pituitary RFX-related complexes by the RFX1 antibody appears complete, suggesting that RFX1 is the predominant species, at least in pituitary cells.
In addition to binding RFX1, PSE-A is also a binding site for NF-1 (Fig. 4) . However, binding of RFX1 and NF-1 to PSE-A appears to be mutually exclusive, as NF-1 was detected only after disruption of the RFX site (Fig. 4A) . This suggests that RFX1 binding is the favored event under the in vitro conditions used and is consistent with our previous inability to see direct binding of NF-1 to PSE-A (6). By extension, the capacity of PSE-A to bind either RFX1 or NF-1 implies that the nuclease protection pattern at PSE-A likely represents a composite of both interactions. There are numerous examples of composite footprint patterns, including one derived from Pit-1 and Sp1 binding in the GH-N proximal promoter region (20, 21) . This suggests that when RFX1 is competed, the binding of NF-1 to PSE-A may still be visualized, explaining why individual RFX elements, such as the PSE-Am6 mutation, appear to be relatively weak competitors of the nuclease protection pattern (Fig. 2C) .
Previous observations of the RFX family have provided evidence that RFX binding can be modified by formation of a complex (reviewed in Ref. 22) . The proximity of PSE-A and PSE-B raises the possibility that RFX1 and NF-1 can interact, and as a result modify their affinity/specificity for 263P. Our ability to coprecipitate NF-1 family members with RFX1 suggests that an interaction between these factors can occur and may contribute to a mechanism regulating gene expression (Fig. 6 ). In addition, the relatively large amounts of oligonucleotide required to see efficient competition of complexes formed on 263P in nuclease protection assays, as compared with individual elements in EMSA, suggest differences in the affinity/ specificity of NF-1 and/or RFX1 complexes under these two assay conditions (Fig. 1) . Regardless of whether RFX1 and NF-1 interact and modify their binding, our assessment of human pituitary chromatin indicates both RFX1 and NF-1 can associate with the 263P region (Fig. 8) .
The presence of P sequences upstream of each member of the human GH gene family that is expressed in the placenta (CS-L, CS-A, GH-V, and CS-B) makes them ideal candidates for involvement in local tissue-specific gene regulation of the GH locus. The detection of 263P hyperacetylation in human placenta, but not pituitary tissue (Fig. 9 and Ref. 4) supports a hypothesis whereby P sequences are not only repressors of placental gene expression in the pituitary, but play a role as an activator in the placenta. The capacity to form distinct pituitary and placental complexes is observed by EMSA using pituitary GC and placental JAR nuclear protein (Norquay, L. D., unpublished results) and supports the potential for separate repressor and activator complexes. It may, however, be inappropriate at this time to limit the analysis of P sequences in the placenta to only 263 bp, as this element was defined based on pituitary repressor function (3, 6) . Although 263P was shown previously to enhance gene expression in the placenta of transgenic mice, the capacity to function in this way was not seen in all lines and was exerted on the pituitary expressed GH-N gene (4) . No consistent activation was seen when full-length P sequences were tested in their native context with the placental CS-A promoter (23) . It therefore remains to be determined what functional role P sequences play in the placenta. Nonetheless, the observation of placental hyperacetylation (Fig. 9) is intriguing, and clearly further structural and functional characterizations of a potential placenta P sequence complex are required.
Previous investigation of the human GH/CS locus revealed two upstream pituitary-specific hypersensitive sites, HS I/II (23), subsequently shown to be essential for pituitary-specific expression of GH-N (23) (24) (25) (26) . Consistent with its regulatory role in vivo, additional characterization revealed that the chromatin containing the HS I/II region was hyperacetylated in primary human GH-secreting pituitary adenoma cells and the pituitaries of transgenic mice (27) . As a part of our study we were able to extend the analysis of chromatin modifications in the human GH/CS locus to normal human pituitaries taken post mortem. Hyperacetylation of the HSI/II region was used to verify the integrity of the pituitary chromatin (data not shown). The use of PCR in our ChIP assays also enabled us to distinguish between the highly homologous GH and CS promoters, which was not possible in previous hybridization approaches (4, 27) . As a result, we observed hyperacetylation at the GH but not the CS promoter in pituitary chromatin (Fig. 9) , which is consistent with their expression patterns in vivo (1) . Pituitaryspecific expression of GH-N is dependent on the transcription factor Pit-1 (25, 26, (28) (29) (30) . Pit-1 has been shown to occupy binding sites in the promoters of both transcribed and nontranscribed genes (31) and has the capacity to recruit both the histone acetyltransferase, CREB-binding protein, and the transcriptional corepressor, nuclear receptor corepressor (N-CoR) (32) . The presence of one vs. two Pit-1 binding sites in the placental GH/CS promoters and/or their relative distances from the upstream HS I/II may contribute to the differences observed in promoter hyperacetylation compared with GH-N (Fig. 9) . We have also proposed that the presence of P sequences upstream of the placental GH/CS promoters, but not GH-N, plays a role in restricting placental gene expression from the pituitary (3). The absence of hyperacetylation at the CS promoter correlated with both lack of 263P hyperacetylation ( Fig. 9) and association of NF-1 and RFX1 with 263P in pituitary tissue (Fig. 8) . Although both NF-1 and RFX1 are known transcriptional activators, they are also associated with repressor activity (5, 33) . In the case of NF-1, down-regulation of Id-1 promoter activity in nonaggressive breast cancer cells was linked to a complex containing both NF-1 and histone deacetylase 1 (HDAC-1) (34). Our observation of NF-1 and RFX1 association with 263P sequences in the pituitary is, to our knowledge, the first example of either of these factors associating with chromatin in human tissue samples. This complex may contribute to a mechanism preventing hyperacetylation of 263P and CS promoter chromatin, thus repressing expression of the placental GH/CS genes in the pituitary.
MATERIALS AND METHODS
Oligonucleotide Sequences
Double-stranded DNA elements were generated by synthesizing and annealing sense and antisense oligonucleotides (Invitrogen, Burlington, Ontario, Canada). The sense strands for each element is provided in Table 1 . The sequences of primers used for PCR of 263P, FGF-16 exon 3, and GH and CS promoters are also given in Table 1 .
Preparation and Fractionation of Nuclear Extracts
Nuclear protein extracts from rat anterior pituitary tumor (GC) cells were made according to published protocols (35) and dialyzed as previously described (36) . Protein concentration of the extracts was assessed using the Bio-Rad Protein Assay (Bio-Rad Laboratories, Inc., Mississauga, Ontario, Canada) with BSA as a standard. Extracts were stored as aliquots at Ϫ70 C.
Deoxyribonuclease (DNase) 1 Protection Assays
DNase protection assays were performed as previously described (6) . Briefly, 25 g of GC cell nuclear protein were preincubated with double-stranded competitor oligonucleotides (1000-5000 pmol excess of the probe) for 15 min on ice. Subsequently, 0.5 ng of 263P fragment probe, radiolabeled at the 3Ј-end, was added to each reaction and incubated for an additional 15 min on ice. DNase digestion proceeded at 26 C for 1 min, and the samples were electrophoresed in a 6% acrylamide gel.
EMSA
EMSA was performed essentially as previously described previously (6) . Competitor oligonucleotides (mass excess of the probe), NF-1, RFX1, RFX2, and RFX3 antibodies (1 l) (6, 9, 14) , or normal rabbit serum (1 l) were preincubated with 5 g of GC cell nuclear extract and 2 g poly dIdC in reaction buffer (10 mM Tris, pH 7.5; 50 mM NaCl; 1 mM dithiothreitol; 1 mM EDTA; 5% glycerol) for 10 min at room temperature in a 20 l final volume. After 10 min, radiolabeled double-stranded oligonucleotide probes were added, and the reactions were incubated an additional 10 min at room temperature before electrophoresis in a 5% acrylamide gel.
Plasmid Constructions
The immediate 5Ј-flanking region of the CS-A gene (Ϫ492/ ϩ6) upstream of the firefly luciferase (Luc) gene (CSp.Luc) as well as 263P.CSp.Luc were previously described (6) . A twostep PCR approach with 263P primers and appropriate mutant oligonucleotides (Table 1 ) was used to introduce mutations into 263P (Taq DNA polymerase; QIAGEN, Mississauga, Ontario, Canada). The final PCR products were inserted as BamHI fragments upstream of the CS-A promoter in CSp.Luc to generate Am2.CSp.Luc, Bm.CSp.Luc, and Am2/Bm.CSp.Luc. All constructs were sequenced. Hemagglutinin (HA) or c-myc (myc)-tagged transcription factors (HA-RFX1, myc-RFX1, myc-NF-1A, myc-NF-1B, myc-NF-1C, and myc-NF-1X) were generated using the epitope-tagged mammalian expression vector set (CLONTECH Laboratories, Inc., Palo Alto, CA). NF-1 cDNAs were isolated from pBSNF-1 vectors (37) and subcloned into XhoI/NotI of pCMV-Myc (CLONTECH Laboratories, Inc.). The RFX1 cDNA was isolated from pSG5RFX1 (38) , blunted with Klenow fragment, and subcloned into the (blunted) SalI site in pCMV-Myc and pCMV-HA (CLONTECH Laboratories, Inc.). 
Mutated sequences are indicated by underlining. 
Immunoprecipitation and Protein Blotting
Immunoprecipitation was carried out with 0.5 mg of total cellular lysate. Lysates were precleared for 30 min at 4 C using nonspecific monoclonal antibodies or rabbit immunoglobulins, followed by a 1-h incubation with Pansorbin Cells (Calbiochem, La Jolla, CA) prepared according to manufacturer's instructions. Specific antibodies to RFX1 (1 l) (9), c-myc (2 g) (CLONTECH Laboratories, Inc.) or, as an unrelated control, rat prostate DLP (1 l) (40) were incubated with precleared supernatants at 4 C for 2 h, and prepared Pansorbin cells were included for overnight incubation. Washes were performed first with supplemented NET Buffer (50 mM Tris, pH 7.5; 500 mM NaCl; 0.1% NP-40; 1 mM EDTA), followed by NET Buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 0.1% NP-40; 1 mM EDTA), and finally 10 mM Tris/0.1% NP-40. Pansorbin cell pellets were resuspended in 40 l of Laemli sample buffer [2% sodium dodecyl sulfate (SDS); 10% glycerol; 100 mM dithiothreitol; 60 mM Tris, pH 6.8; and 0.001% bromophenol blue], boiled for 5 min, and 20 l was resolved by SDS-PAGE in an 8% gel. Gels were transferred and immobilized on polyvinylidine difluoride membranes (Roche Diagnostics) and blocked. Immunodetection was performed for 1 h (rabbit RFX1 antibodies, 1:10,000) or overnight (mouse c-myc antibodies, 2 g/ml) at 4 C, and detection of antibody-antigen complexes was performed using BM chemiluminescence blotting substrate (POD, Roche Diagnostics) according to manufacturer's instructions. Complexes were visualized on Kodak Biomax film (Amersham Pharmacia Biotech Biosciences, Baie d'Urfé , Qué bec, Canada).
Nuclei Isolation and ChIP
Postmortem human pituitary tissue was obtained from the Human Pituitary Repository in the Protein and Polypeptide Laboratory at the University of Manitoba, and placentas were from normal term deliveries at the Health Science Centre (Winnipeg, Manitoba). For each ChIP assay, nuclei were isolated from placenta tissue or pooled (3-6) human pituitary samples as previously described (2) , and 50 l NF-1 (H-300) (Santa Cruz Biotechnology, Inc.). The following day, 300 l of protein A sepharose and 50 g of sheared salmon sperm DNA were added for 1 h. Samples were washed for 10 min at 4 C in 5 ml of wash buffer as follows: low-salt buffer (20 mM Tris, pH 8; 150 mM NaCl; 2 mM EDTA; 1% Triton X-100; 0.1% SDS), high-salt buffer (20 mM Tris, pH 8; 500 mM NaCl; 2 mM EDTA; 1% Triton X-100; 0.1% SDS), LiCl buffer (10 mM Tris, pH 8; 0.25 M LiCl; 1 mM EDTA; 1% deoxycholic acid Na salt; 1% NP-40), and twice in TE buffer (10 mM Tris, pH 8; 1 mM EDTA). Samples were eluted twice in 1.25 ml elution buffer (1% SDS, 0.1 M NaHCO 3 ) for 15 min at room temperature, and cross-links were reversed for 6 h at 68 C. DNA was isolated using QIAquick columns (QIAGEN, Chatsworth, CA) according to manufacturer's instructions. PCR was carried out with 10 ng of input DNA or 5 l eluted (bound) DNA per PCR reaction (Taq DNA polymerase; QIAGEN) at 55 C annealing temperature for 28 cycles. PCR primer pairs are listed in Table 1 . For amplification of 263P, 263(F) and PSE-Aext(R) were used as primers.
Statistical Analysis
Statistical analysis was done using a two-tailed, unpaired Student's t test. A value of P Ͻ 0.05 is considered statistically significant. In figures, *, P Ͻ 0.05; **, P Ͻ 0.01; and ***, P Ͻ 0.001.
